What's New

Explore the latest information on TriNav and the PEDD approach.

Image of a TriNav clinical studies product.

Enhancing the T:N Ratio with the TriNav® Infusion System

Pressure-Enabled Drug Delivery™ Significantly Improves Tumor Targeting in Clinical Study

Introducing TriNav Case Snippets – Interventional Radiologists Showcasing Real-World Experience

Real-World Evidence Demonstrates the Benefits of TriNav® Infusion System

Improving the T:N Ratio is Especially Important in Complex Patients

Real-World Experience With TriNav LV

The TriNav® LV Infusion System With SmartValve® Technology Is Now Available

Effective & Targeted Treatment with Proximal Delivery Using TriNav

Elevating TACE Outcomes with TriNav

Case Imaging: TriNav Improves Tumor Penetration in Glass Y90 TARE

TriNav’s SmartValve: Consistent Therapy Delivery

CMS granted TriNav a unique procedural code reimbursed at Endovascular Level 4: APC 5194

Durable Response in Recurrent HCC After Y90 Treatment with TriNav

TriNav Increases Glass Microsphere Delivery vs. Traditional Microcatheters

Honoring Liver Cancer Awareness Month: Advancing Patient Care Together

Real-World Evidence suggests TriNav may reduce post-embolization complications

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

New TriNav Data in JVIR

Improving the T:N ratio with TriNav

The complex liver cancer patient has been shown to benefit from TriNav’s Pressure-Enabled Drug Delivery™ (PEDD™) approach

Improving T:N Ratio in Complex Patients with the TriNav^® Infusion System